Table 1.
1 | 2 | 3 | 4 | |
---|---|---|---|---|
C. albicans, ATCC 14503 | 0.25 | 0.25 | 0.50 | 0.50 |
C. albicans 96–489b | 0.06 | <0.03 | 0.12 | 0.12 |
C. albicans UCD-FR1b | 0.25 | 0.12 | 0.50 | 0.50 |
C. glabrata | 0.12 | 0.06 | 0.12 | 0.12 |
C. krusei | 0.06 | 0.12 | 0.12 | 0.12 |
Cryptococcus neoformans var. gattii | 0.12 | 0.25 | 0.12 | 0.50 |
C. neoformans var. grubii | 0.12 | 0.25 | 0.12 | 0.50 |
The in vitro susceptibilities were determined by the microbroth dilution method according to the guidelines of the National Committee for Clinical Laboratory Standards (NCCLS).
Fluconazole-resistant (MIC >64 (μg/mL).